PL3074032T3 - Pochodne kwasów tłuszczowych dimerycznych inhibitorów psd-95 - Google Patents

Pochodne kwasów tłuszczowych dimerycznych inhibitorów psd-95

Info

Publication number
PL3074032T3
PL3074032T3 PL14821058T PL14821058T PL3074032T3 PL 3074032 T3 PL3074032 T3 PL 3074032T3 PL 14821058 T PL14821058 T PL 14821058T PL 14821058 T PL14821058 T PL 14821058T PL 3074032 T3 PL3074032 T3 PL 3074032T3
Authority
PL
Poland
Prior art keywords
psd
fatty acid
acid derivatives
dimeric inhibitors
dimeric
Prior art date
Application number
PL14821058T
Other languages
English (en)
Inventor
Kristian STRØMGAARD
Anders Bach
Klaus Bertram NISSEN
Original Assignee
University Of Copenhagen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Copenhagen filed Critical University Of Copenhagen
Publication of PL3074032T3 publication Critical patent/PL3074032T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL14821058T 2013-12-01 2014-11-26 Pochodne kwasów tłuszczowych dimerycznych inhibitorów psd-95 PL3074032T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201370735 2013-12-01
PCT/DK2014/050402 WO2015078477A1 (en) 2013-12-01 2014-11-26 Fatty acid derivatives of dimeric inhibitors of psd-95
EP14821058.6A EP3074032B1 (en) 2013-12-01 2014-11-26 Fatty acid derivatives of dimeric inhibitors of psd-95

Publications (1)

Publication Number Publication Date
PL3074032T3 true PL3074032T3 (pl) 2019-06-28

Family

ID=52272794

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14821058T PL3074032T3 (pl) 2013-12-01 2014-11-26 Pochodne kwasów tłuszczowych dimerycznych inhibitorów psd-95

Country Status (14)

Country Link
US (1) US20160303245A1 (pl)
EP (1) EP3074032B1 (pl)
JP (1) JP6633523B2 (pl)
KR (1) KR20160091980A (pl)
CN (1) CN105828832A (pl)
AU (1) AU2014356912B2 (pl)
BR (1) BR112016012391A2 (pl)
CA (1) CA2931694C (pl)
DK (1) DK3074032T3 (pl)
ES (1) ES2716890T3 (pl)
IL (1) IL245904A (pl)
MX (1) MX2016006966A (pl)
PL (1) PL3074032T3 (pl)
WO (1) WO2015078477A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033371T2 (en) 2013-03-21 2017-11-28 Sanofi Aventis Deutschland Process for the preparation of peptide products containing a ring imide
EP2976331B1 (en) 2013-03-21 2017-03-01 Sanofi-Aventis Deutschland GmbH Synthesis of hydantoin containing peptide products
CN107226840A (zh) * 2017-05-04 2017-10-03 西安交通大学 一种细胞穿膜肽透皮吸收促进剂及其制备方法和应用
CN109030662B (zh) * 2018-09-14 2021-04-13 广西医科大学第一附属医院 检测致痫大鼠海马组织谷氨酸及r-氨基丁酸含量的方法
JP2023506598A (ja) 2020-03-06 2023-02-16 ユニバーシティ オブ コペンハーゲン Ｐｉｃｋ１の脂質共役ペプチド阻害剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9215780D0 (en) * 1992-07-24 1992-09-09 Univ London Pharmacy Peptide compounds
ES2542522T3 (es) 2008-07-09 2015-08-06 University Of Copenhagen Péptidos modificados como inhibidores potentes de la interacción entre receptor de NMDA/PSD-95
EP2707014B1 (en) 2011-05-13 2015-06-17 Københavns Universitet (University of Copenhagen) High-affinity, dimeric inhibitors of psd-95 and their use for treating ischemic brain damage and pain
MX339993B (es) * 2011-05-13 2016-06-21 Københavns Univ (University Of Copenhagen) Inhibidores dimericos de alta afinidad de psd-95 como neuroprotectores eficientes contra daño isquemico cerebral y para el tratamiento de dolor.
WO2013151538A1 (en) * 2012-04-03 2013-10-10 Empire Technology Development Llc Fluorescent labeling of living cells

Also Published As

Publication number Publication date
EP3074032B1 (en) 2018-12-26
AU2014356912B2 (en) 2019-08-01
CA2931694A1 (en) 2015-06-04
JP6633523B2 (ja) 2020-01-22
MX2016006966A (es) 2017-01-19
WO2015078477A1 (en) 2015-06-04
DK3074032T3 (en) 2019-04-15
CN105828832A (zh) 2016-08-03
IL245904A (en) 2017-10-31
IL245904A0 (en) 2016-07-31
KR20160091980A (ko) 2016-08-03
US20160303245A1 (en) 2016-10-20
CA2931694C (en) 2020-12-01
JP2017501132A (ja) 2017-01-12
EP3074032A1 (en) 2016-10-05
BR112016012391A2 (pt) 2017-09-26
AU2014356912A1 (en) 2016-06-09
ES2716890T3 (es) 2019-06-17

Similar Documents

Publication Publication Date Title
HK1222646A1 (zh) 作為溴結構域抑制劑的苯並咪唑衍生物
HK1220460A1 (zh) 組蛋白脫甲基酶的抑制劑
PT3080100T (pt) Inibidores de desmetilase-1 específica de lisina
HK1210470A1 (en) Hydropyrrolopyrrole derivatives for use as fatty acid synthase inhibitors
HK1211027A1 (en) Pyrrolotriazinone derivatives as pi3k inhibitors pi3k
HK1217431A1 (zh) 作為分揀蛋白抑制劑的 -取代的- -取代的鄰氨甲酰苯甲酸
HK1219271A1 (zh) 作爲 抑制劑的化合物和組合物
IL245904A (en) Fatty acid derivatives of the dimeric psd-95 inhibitors
HK1222339A1 (zh) 金屬-β-內酰胺酶的抑制劑
EP2872143A4 (en) DI- AND TRI-HETEROARYL DERIVATIVES AS INHIBITORS OF PROTEIN AGGREGATION
IL240763A0 (en) The halopyrazoles as thrombin inhibitors
HK1202452A1 (en) Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
IL240293A0 (en) Transformed histories of carboxylic acids and pharmaceutical preparations containing them
EP2968324A4 (en) SUBSTITUTED PYRIDONE DERIVATIVES AS PDE10 INHIBITORS
EP3010913A4 (en) Piperidinolbenzimidazole derivatives as MPGE-1 inhibitors
EP2986112A4 (en) PREPARATION AND USE OF FULVINIC ACID DERIVATIVES
HK1226072A1 (zh) 作為bcl-3抑制劑的2-苯甲酰氨基苯甲酰胺衍生物
PT2961736T (pt) Inibidores de histona desmetilases